AAV vector integration sites in mouse hepatocellular carcinoma - PubMed (original) (raw)
. 2007 Jul 27;317(5837):477.
doi: 10.1126/science.1142658.
Affiliations
- PMID: 17656716
- DOI: 10.1126/science.1142658
AAV vector integration sites in mouse hepatocellular carcinoma
Anthony Donsante et al. Science. 2007.
Abstract
Adeno-associated viruses (AAV) are promising gene therapy vectors that have little or no acute toxicity. We show that normal mice and mice with mucopolysaccharidosis VII (MPS VII) develop hepatocellular carcinoma (HCC) after neonatal injection of an AAV vector expressing b-glucuronidase. AAV proviruses were isolated from four tumors and were all located within a 6-kilobase region of chromosome 12. This locus encodes several imprinted transcripts, small nucleolar RNAs (snoRNAs), and microRNAs. Transcripts from adjacent genes encoding snoRNAs and microRNAs were overexpressed in tumors. Our findings implicate this locus in the development of HCC and raise concerns over the clinical use of AAV vectors.
Similar articles
- Assessing the potential for AAV vector genotoxicity in a murine model.
Li H, Malani N, Hamilton SR, Schlachterman A, Bussadori G, Edmonson SE, Shah R, Arruda VR, Mingozzi F, Wright JF, Bushman FD, High KA. Li H, et al. Blood. 2011 Mar 24;117(12):3311-9. doi: 10.1182/blood-2010-08-302729. Epub 2010 Nov 24. Blood. 2011. PMID: 21106988 Free PMC article. - Adeno-associated virus vector integration junctions.
Rutledge EA, Russell DW. Rutledge EA, et al. J Virol. 1997 Nov;71(11):8429-36. doi: 10.1128/JVI.71.11.8429-8436.1997. J Virol. 1997. PMID: 9343199 Free PMC article. - Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy.
Chandler RJ, LaFave MC, Varshney GK, Trivedi NS, Carrillo-Carrasco N, Senac JS, Wu W, Hoffmann V, Elkahloun AG, Burgess SM, Venditti CP. Chandler RJ, et al. J Clin Invest. 2015 Feb;125(2):870-80. doi: 10.1172/JCI79213. Epub 2015 Jan 20. J Clin Invest. 2015. PMID: 25607839 Free PMC article. - Recent advances in various adeno-associated viruses (AAVs) as gene therapy agents in hepatocellular carcinoma.
Hadi M, Qutaiba B Allela O, Jabari M, Jasoor AM, Naderloo O, Yasamineh S, Gholizadeh O, Kalantari L. Hadi M, et al. Virol J. 2024 Jan 12;21(1):17. doi: 10.1186/s12985-024-02286-1. Virol J. 2024. PMID: 38216938 Free PMC article. Review. - Integration and the risk of liver cancer-Is there a real risk?
Kasimsetty A, Sabatino DE. Kasimsetty A, et al. J Viral Hepat. 2024 Apr;31 Suppl 1:26-34. doi: 10.1111/jvh.13915. J Viral Hepat. 2024. PMID: 38606944 Review.
Cited by
- Disease correction by combined neonatal intracranial AAV and systemic lentiviral gene therapy in Sanfilippo Syndrome type B mice.
Heldermon CD, Qin EY, Ohlemiller KK, Herzog ED, Brown JR, Vogler C, Hou W, Orrock JL, Crawford BE, Sands MS. Heldermon CD, et al. Gene Ther. 2013 Sep;20(9):913-21. doi: 10.1038/gt.2013.14. Epub 2013 Mar 28. Gene Ther. 2013. PMID: 23535899 Free PMC article. - Lessons Learned from Animal Models of Inherited Bleeding Disorders.
Nichols TC. Nichols TC. Hematol Educ. 2014 Jun;8(1):39-46. Hematol Educ. 2014. PMID: 26052366 Free PMC article. - A universal system to select gene-modified hepatocytes in vivo.
Nygaard S, Barzel A, Haft A, Major A, Finegold M, Kay MA, Grompe M. Nygaard S, et al. Sci Transl Med. 2016 Jun 8;8(342):342ra79. doi: 10.1126/scitranslmed.aad8166. Sci Transl Med. 2016. PMID: 27280686 Free PMC article. - Hemophilia Healing with AAV: Navigating the Frontier of Gene Therapy.
Khan SU, Khan MU, Suleman M, Inam A, Din MAU. Khan SU, et al. Curr Gene Ther. 2024;24(4):265-277. doi: 10.2174/0115665232279893231228065540. Curr Gene Ther. 2024. PMID: 38284735 Review. - AAV Engineering for Improving Tropism to the Central Nervous System.
Ghauri MS, Ou L. Ghauri MS, et al. Biology (Basel). 2023 Jan 26;12(2):186. doi: 10.3390/biology12020186. Biology (Basel). 2023. PMID: 36829465 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases